New hope for HER2+ breast cancer: RC48 combo tested after standard ADC fails
NCT ID NCT07366840
First seen Jan 27, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This study tests whether a new drug combination (RC48 plus chemotherapy) works better than standard treatments for people with HER2-positive advanced breast cancer whose disease has worsened after prior therapy with a topoisomerase I inhibitor antibody-drug conjugate. About 268 women will be randomly assigned to receive either the experimental combo or standard care (trastuzumab or inetetamab plus chemo). The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Disitamab vedotin (RC48) combined with gemcitabine or capecitabine, with or without trastuzumab or inetetamab
What this could lead to
If successful, this could offer a new treatment option for HER2-positive advanced breast cancer patients whose disease has worsened after prior antibody-drug conjugate therapy.
What could go wrong
This is an early-stage trial (Phase 2/3) with only 268 participants, so results may not apply to all patients. The combination therapy may cause significant side effects, and there is no guarantee it will improve survival or quality of life.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.